{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T02:35:59Z","timestamp":1770690959009,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10120-021-01233-1","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T14:06:01Z","timestamp":1630505161000},"page":"226-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Insertion\u2013deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab"],"prefix":"10.1007","volume":"25","author":[{"given":"Hyung-Don","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meesun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0783-6583","authenticated-orcid":false,"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"1233_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3389\/fonc.2020.00763","volume":"10","author":"R Sundar","year":"2020","unstructured":"Sundar R, Smyth EC, Peng S, et al. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Front Oncol. 2020;10:763. https:\/\/doi.org\/10.3389\/fonc.2020.00763.","journal-title":"Front Oncol"},{"key":"1233_CR2","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/s0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(17)31827-5.","journal-title":"Lancet"},{"key":"1233_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"1233_CR4","doi-asserted-by":"crossref","unstructured":"Chen L, Kang Y, Tanimoto M, et al. ATTRACTION-04 (ONO-4538\u201337): A randomized, multicenter, phase 2\/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer. Ann Oncol 2017;28:v266.","DOI":"10.1093\/annonc\/mdx369.159"},{"key":"1233_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1634\/theoncologist.2018-0221","volume":"24","author":"L Fashoyin-Aje","year":"2019","unstructured":"Fashoyin-Aje L, Donoghue M, Chen H, et al. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. Oncologist. 2019;24:103\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2018-0221.","journal-title":"Oncologist"},{"key":"1233_CR6","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449\u201358. https:\/\/doi.org\/10.1038\/s41591-018-0101-z.","journal-title":"Nat Med"},{"key":"1233_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102024","volume":"86","author":"MJM van Velzen","year":"2020","unstructured":"van Velzen MJM, Derks S, van Grieken NCT, et al. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev. 2020;86: 102024. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102024.","journal-title":"Cancer Treat Rev"},{"key":"1233_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733.","journal-title":"Science"},{"key":"1233_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo GD, et al. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021;39:154\u201373. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.001.","journal-title":"Cancer Cell"},{"key":"1233_CR10","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377:2500\u20131. https:\/\/doi.org\/10.1056\/NEJMc1713444.","journal-title":"N Engl J Med"},{"key":"1233_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202\u20136. https:\/\/doi.org\/10.1038\/s41588-018-0312-8.","journal-title":"Nat Genet"},{"key":"1233_CR12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365. https:\/\/doi.org\/10.1016\/s1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"key":"1233_CR13","doi-asserted-by":"crossref","unstructured":"Paz-Ares L, Langer C, Novello S, et al. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407. 2019;30:v917\u2013v8.","DOI":"10.1093\/annonc\/mdz394.078"},{"key":"1233_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/s1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic S, Litchfield K, Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18:1009\u201321. https:\/\/doi.org\/10.1016\/s1470-2045(17)30516-8.","journal-title":"Lancet Oncol"},{"key":"1233_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith CC, Selitsky SR, Chai S, et al. Alternative tumour-specific antigens. Nat Rev Cancer. 2019;19:465\u201378. https:\/\/doi.org\/10.1038\/s41568-019-0162-4.","journal-title":"Nat Rev Cancer"},{"key":"1233_CR16","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.jtho.2019.06.016","volume":"14","author":"YK Chae","year":"2019","unstructured":"Chae YK, Viveiros P, Lopes G, et al. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. J Thorac Oncol. 2019;14:1807\u201317. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.016.","journal-title":"J Thorac Oncol"},{"key":"1233_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s40425-019-0596-y","volume":"7","author":"M Sui","year":"2019","unstructured":"Sui M, Li Y, Wang H, et al. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. J Immunother Cancer. 2019;7:125. https:\/\/doi.org\/10.1186\/s40425-019-0596-y.","journal-title":"J Immunother Cancer"},{"key":"1233_CR18","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","volume":"10","author":"M Kim","year":"2019","unstructured":"Kim M, Mun H, Sung CO, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10:3991. https:\/\/doi.org\/10.1038\/s41467-019-11867-6.","journal-title":"Nat Commun"},{"key":"1233_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jmoldx.2018.09.005","volume":"21","author":"JE Kim","year":"2019","unstructured":"Kim JE, Chun SM, Hong YS, et al. Mutation Burden and I Index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing. J Mol Diagn. 2019;21:241\u201350. https:\/\/doi.org\/10.1016\/j.jmoldx.2018.09.005.","journal-title":"J Mol Diagn"},{"key":"1233_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","volume":"120","author":"H Chae","year":"2019","unstructured":"Chae H, Kim D, Yoo C, et al. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. Eur J Cancer. 2019;120:31\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.022.","journal-title":"Eur J Cancer"},{"key":"1233_CR21","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jmoldx.2018.06.002","volume":"20","author":"SM Chun","year":"2018","unstructured":"Chun SM, Sung CO, Jeon H, et al. Next-Generation Sequencing Using S1 Nuclease for Poor-Quality Formalin-Fixed. Paraffin-Embedded Tumor Specimens J Mol Diagn. 2018;20:802\u201311. https:\/\/doi.org\/10.1016\/j.jmoldx.2018.06.002.","journal-title":"Paraffin-Embedded Tumor Specimens J Mol Diagn"},{"key":"1233_CR22","doi-asserted-by":"crossref","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang Y-J, et al. The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061. American Society of Clinical Oncology; 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.4537"},{"key":"1233_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fonc.2020.00314","volume":"10","author":"J Kim","year":"2020","unstructured":"Kim J, Kim B, Kang SY, et al. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. Front Oncol. 2020;10:314. https:\/\/doi.org\/10.3389\/fonc.2020.00314.","journal-title":"Front Oncol"},{"key":"1233_CR24","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","volume":"30","author":"F Wang","year":"2019","unstructured":"Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432. Ann Oncol. 2019;30:1479\u201386. https:\/\/doi.org\/10.1093\/annonc\/mdz197.","journal-title":"Ann Oncol"},{"key":"1233_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.aau0447","volume":"364","author":"R Mandal","year":"2019","unstructured":"Mandal R, Samstein RM, Lee KW, et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science. 2019;364:485\u201391. https:\/\/doi.org\/10.1126\/science.aau0447.","journal-title":"Science"},{"key":"1233_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/jco.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang YJ, Piha-Paul SA, et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2019;37:318\u201327. https:\/\/doi.org\/10.1200\/jco.2018.78.2276.","journal-title":"J Clin Oncol"},{"key":"1233_CR27","doi-asserted-by":"publisher","unstructured":"Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 2019;4. https:\/\/doi.org\/10.1172\/jci.insight.126908.","DOI":"10.1172\/jci.insight.126908"},{"key":"1233_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12967-019-1941-0","volume":"17","author":"H Cai","year":"2019","unstructured":"Cai H, Jing C, Chang X, et al. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing. J Transl Med. 2019;17:189. https:\/\/doi.org\/10.1186\/s12967-019-1941-0.","journal-title":"J Transl Med"},{"key":"1233_CR29","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/annonc\/mdz205","volume":"30","author":"J Budczies","year":"2019","unstructured":"Budczies J, Allg\u00e4uer M, Litchfield K, et al. Optimizing panel-based tumor mutational burden (TMB) measurement. Ann Oncol. 2019;30:1496\u2013506. https:\/\/doi.org\/10.1093\/annonc\/mdz205.","journal-title":"Ann Oncol"},{"key":"1233_CR30","doi-asserted-by":"publisher","unstructured":"Vokes NI, Liu D, Ricciuti B, et al. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol 2019;3. https:\/\/doi.org\/10.1200\/po.19.00171.","DOI":"10.1200\/po.19.00171"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-021-01233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-021-01233-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-021-01233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T01:05:13Z","timestamp":1661994313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-021-01233-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1007\/s10120-021-01233-1","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"21 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing directly related to this work. Outside of this work, YKK has served as a consultant for ALX Oncology, Zymeworks, Amgen, Novartis, Macrogenics, Daehwa, Blueprint, Surface Oncolgy, BMS, and Merck (MSD).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}